T2 Biosystems (NASDAQ:TTOO) versus Minerva Surgical (NASDAQ:UTRS) Head-To-Head Review

Valuation & Earnings

This table compares Minerva Surgical and T2 Biosystems”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Surgical	$51.69 million	0.00	-$34.11 million	($8.21)	0.00
T2 Biosystems	$7.68 million	0.01	-$50.08 million	($3.89)	0.00

Minerva Surgical has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

23.2% of T2 Biosystems shares are owned by institutional investors. 8.5% of Minerva Surgical shares are owned by company insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Minerva Surgical has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.

Profitability

This table compares Minerva Surgical and T2 Biosystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Minerva Surgical	N/A	N/A	N/A
T2 Biosystems	-563.16%	N/A	-174.06%

Summary

Minerva Surgical beats T2 Biosystems on 7 of the 10 factors compared between the two stocks.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.